Objective:
To evaluate the efficacy and durability of Vabysmo (faricimab) in treating polypoidal choroidal vasculopathy (PCV) in Asian patients.
Key Findings:
- Patients gained an average of 8.9 letters in best-corrected visual acuity (BCVA) after 1 year.
- More than 50% of patients extended treatment intervals to 20 weeks.
- 61% of patients showed complete regression of polypoidal lesions.
- 86% achieved lesion inactivation.
Interpretation:
The findings suggest that Vabysmo may significantly reduce treatment burden while maintaining vision in patients with PCV, a major cause of vision loss in Asia.
Limitations:
- The study is ongoing, and long-term efficacy and safety data beyond one year are still being collected.
Conclusion:
Vabysmo demonstrates potential as a durable treatment option for PCV, addressing the increasing AMD cases in Asia's aging population.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.